Oppenheimer Cuts Prestige Consumer Healthcare (NYSE:PBH) Price Target to $72.00

Key Points

• Oppenheimer has cut the price target for Prestige Consumer Healthcare (NYSE:PBH) from $82.00 to $72.00, while maintaining an "outperform" rating.
• Zacks Research has downgraded PBH from a "hold" rating to a "strong sell," reflecting growing concerns among analysts about the stock's performance.
• Prestige Consumer Healthcare reported a 6.6% decrease in revenue compared to the previous year, with earnings of $0.95 per share, missing analysts' expectations of $1.01.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) had its target price dropped by equities researchers at Oppenheimer from $82.00 to $72.00 in a research report issued on Tuesday, MarketBeat reports. The firm presently has an "outperform" rating on the stock. Oppenheimer's target price points to a potential upside of 15.31% from the stock's current price.

Other research analysts also recently issued research reports about the stock. Zacks Research downgraded shares of Prestige Consumer Healthcare from a "hold" rating to a "strong sell" rating in a report on Thursday, September 4th. Wall Street Zen downgraded shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Weiss Ratings restated a "hold (c)" rating on shares of Prestige Consumer Healthcare in a report on Wednesday, October 8th. Sidoti upgraded shares of Prestige Consumer Healthcare from a "neutral" rating to a "buy" rating and set a $80.00 price objective on the stock in a report on Wednesday, September 24th. Finally, Canaccord Genuity Group lowered their target price on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of "Hold" and an average target price of $90.60.

Prestige Consumer Healthcare Stock Up 0.4%

Shares of NYSE:PBH traded up $0.26 during trading on Tuesday, reaching $62.44. 9,812 shares of the company traded hands, compared to its average volume of 416,130. The firm has a market cap of $3.07 billion, a P/E ratio of 14.66, a price-to-earnings-growth ratio of 1.96 and a beta of 0.44. The firm has a fifty day simple moving average of $64.28 and a 200 day simple moving average of $75.10. The company has a quick ratio of 2.99, a current ratio of 4.38 and a debt-to-equity ratio of 0.55. Prestige Consumer Healthcare has a 1-year low of $60.15 and a 1-year high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing analysts' consensus estimates of $1.01 by ($0.06). The business had revenue of $249.53 million for the quarter, compared to the consensus estimate of $260.71 million. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The firm's revenue for the quarter was down 6.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.90 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. Analysts anticipate that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of large investors have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC lifted its position in shares of Prestige Consumer Healthcare by 4.6% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,592,375 shares of the company's stock worth $100,893,000 after purchasing an additional 70,376 shares in the last quarter. Carnegie Lake Advisors LLC lifted its position in shares of Prestige Consumer Healthcare by 37.0% during the third quarter. Carnegie Lake Advisors LLC now owns 19,274 shares of the company's stock worth $1,203,000 after purchasing an additional 5,210 shares in the last quarter. Three Seasons Wealth LLC acquired a new position in shares of Prestige Consumer Healthcare during the third quarter worth approximately $347,000. Inspire Investing LLC lifted its position in shares of Prestige Consumer Healthcare by 48.6% during the third quarter. Inspire Investing LLC now owns 7,265 shares of the company's stock worth $453,000 after purchasing an additional 2,375 shares in the last quarter. Finally, Milestone Asset Management LLC acquired a new position in shares of Prestige Consumer Healthcare during the third quarter worth approximately $861,000. 99.95% of the stock is currently owned by institutional investors and hedge funds.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.